Moderna IPO
Moderna is a biotechnology company that develops messenger RNA therapeutics and vaccines to create new medicines for infectious diseases, immuno-oncology, rare diseases, and cardiovascular diseases. The company gained global prominence for developing one of the first COVID-19 vaccines.
Key Facts
| Industry | Biotechnology |
| Founded | 2010 |
| Headquarters | Cambridge, MA |
| Employees | ~5,000 |
| Website | modernatx.com |
| Funding | Public company (NASDAQ: MRNA) |
About Moderna
Moderna is a biotechnology company that pioneered the development of messenger RNA (mRNA) therapeutics and vaccines, becoming globally recognized for its COVID-19 vaccine. The company's platform technology enables the design of mRNA medicines that instruct cells to produce proteins that can prevent, treat, or cure diseases. Beyond COVID-19, Moderna is developing mRNA-based treatments for cancer, rare diseases, autoimmune conditions, and other infectious diseases.
The company's success with its COVID-19 vaccine validated the mRNA platform and established Moderna as a leader in next-generation biotechnology. Moderna's approach allows for rapid development and modification of treatments compared to traditional vaccine and drug development methods. The company is leveraging its platform and manufacturing capabilities to build a diverse pipeline addressing unmet medical needs across multiple therapeutic areas, positioning mRNA technology as a transformative approach to medicine.
IPO Status
Moderna went public in December 2018, trading on NASDAQ under the ticker MRNA. The company's IPO raised $604 million, making it one of the largest biotech IPOs at the time. Moderna's stock price surged dramatically during the COVID-19 pandemic as its mRNA vaccine became a cornerstone of global vaccination efforts. The company has continued to expand its mRNA platform beyond COVID-19 vaccines into other therapeutic areas and maintains a robust pipeline of mRNA-based treatments.
Competitors
Frequently Asked Questions
Does Moderna have a stock?
Yes, Moderna completed its IPO in December 2018 and trades publicly on NASDAQ under the ticker MRNA. The company has been publicly traded for over five years.
When is the Moderna IPO date?
Moderna already completed its IPO in December 2018. The company is currently publicly traded and does not need another IPO.
How can I buy Moderna stock?
You can buy Moderna stock through any brokerage account using the ticker symbol MRNA on NASDAQ. The stock is widely available to retail investors during regular trading hours.
Don't Miss the Next Big IPO
Get notified when the next major company files for an IPO. Daily alerts delivered to your inbox.
Get IPO Alerts